PETV
PetVivo Holdings, Inc.1.1600
-0.0300-2.52%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
38.95MP/E (TTM)
-Basic EPS (TTM)
-0.40Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Debt-to-equity conversion completed
PetVivo Holdings converted $2,018,155 in outstanding promissory notes from four shareholders into 3,669,806 restricted common shares at prices ranging from $0.50 to $0.75 per share, effective September 30, 2025. This fully settles the debt, including $1.85 million principal and $168,155 accrued interest, eliminating related obligations. The move strengthens the balance sheet by swapping liabilities for equity. No further debt remains with these lenders.
10-Q
Q1 FY2026 results
PetVivo Holdings boosted revenues to $297,500 in Q1 FY2026 ended June 30, 2025, up 140% year-over-year from $123,751, thanks to Precise PRP sales under its new VetStem license alongside Spryng product gains; gross profit climbed to $186,726 from $110,757, yet operating loss narrowed to $1.8M from $2.0M on tighter G&A and R&D spending. Net loss widened to $2.3M or $0.09 per share from $2.0M or $0.11, driven by a $320K unrealized derivative hit and $149K asset disposal loss, while Series B dividends added $29K drag—anti-dilution kept EPS steady despite 30% more shares. Cash swelled to $3.3M after $4.4M Series B funding, covering $1.6M operating burn; non-GAAP metrics not disclosed in the 10-Q. Signed exclusive VetStem deal in February 2025 for $2M fee (cash/stock/future payments), amortizing over 60 months with 3-4.5% royalties starting month seven. Lease terminated June 2025 for $315K fees. Debt stands at $1.5M convertible notes (10-12% rates, maturities to December 2025). Competition from NSAIDs and injectables pressures adoption.
10-K
FY2025 results
PetVivo Holdings posted FY2025 revenue of $1.13 million, up 17% y/y from $969K in FY2024, driven by Spryng® sales to distributors ($956K) and clinics ($176K), with Precise PRP adding momentum in Q4 via the VetStem license. While annual operating expenses fell 21% to $9.05 million on lower G&A and marketing, Q4 showed sequential revenue acceleration from Q3, though R&D rose 13% y/y to $1.58 million for clinical studies. Net loss narrowed to $8.40 million ($0.41/share) from $10.96 million ($0.78/share), aided by 47% more diluted shares (20.5 million). Liquidity stood at $228K cash with $2.09 million in notes, bolstered by $5 million Series B funding; no dividends or buybacks, but capex supported manufacturing expansion. No annual guidance disclosed in the 10-K. Yet distribution shifts risk quarterly sales volatility.
BVS
Bioventus Inc.
7.52+0.02
IVP
Inspire Veterinary Partners, In
0.05-0.00
LIVN
LivaNova PLC
63.08+0.02
PETS
PetMed Express, Inc.
3.90+1.03
PTPI
Petros Pharmaceuticals, Inc.
0.01-0.00
RBOT
Vicarious Surgical Inc.
2.43-0.04
RDGL
Vivos Inc.
0.07-0.00
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
ZIVO
Zivo Bioscience, Inc.
9.00+0.00
ZOMDF
Zomedica Corp.
0.11+0.00